|
 |
| ORIGINAL ARTICLE |
|
| Year : 2013 | Volume
: 5
| Issue : 1 | Page : 6-11 |
|
|
A randomized evaluator blinded study of effect of microneedling in androgenetic alopecia: A pilot study
Rachita Dhurat, MS Sukesh, Ganesh Avhad, Ameet Dandale, Anjali Pal, Poonam Pund
Department of Dermatology, L.T.M. Medical College and General Hospital, Sion, Mumbai, Maharashtra, India
| Date of Web Publication | 6-Jul-2013 |
Correspondence Address:
Rachita Dhurat
B 14/2 Maitri Park CHS, Sion Trombay Road, Chembur, Mumbai - 400 071, Maharashtra
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0974-7753.114700
 Abstract | | |
Introduction: Dermal papilla (DP) is the site of expression of various hair growth related genes. Various researches have demonstrated the underlying importance of Wnt proteins and wound growth factors in stimulating DP associated stem cells. Microneedling works by stimulation of stem cells and inducing activation of growth factors. Materials and Methods: Hundred cases of mild to moderate (III vertex or IV) androgenetic alopecia (AGA) were recruited into 2 groups. After randomization one group was offered weekly microneedling treatment with twice daily 5% minoxidil lotion (Microneedling group); other group was given only 5% minoxidil lotion. After baseline global photographs, the scalp were shaved off to ensure equal length of hair shaft in all. Hair count was done in 1 cm 2 targeted fixed area (marked with tattoo) at baseline and at end of therapy (week 12). The 3 primary efficacy parameters assessed were: Change from baseline hair count at 12 weeks, patient assessment of hair growth at 12 weeks, and investigator assessment of hair growth at 12 weeks. A blinded investigators evaluated global photographic response. The response was assessed by 7- point scale. Results: (1) Hair counts - The mean change in hair count at week 12 was significantly greater for the Microneedling group compared to the Minoxidil group (91.4 vs 22.2 respectively). (2) Investigator evaluation - Forty patients in Microneedling group had +2 to +3 response on 7-point visual analogue scale, while none showed the same response in the Minoxidil group. (3) Patient evaluation - In the Microneedling group, 41 (82%) patients reported more than 50% improvement versus only 2 (4.5%) patients in the Minoxidil group. Unsatisfied patients to conventional therapy for AGA got good response with Microneedling treatment. Conclusion: Dermaroller along with Minoxidil treated group was statistically superior to Minoxidil treated group in promoting hair growth in men with AGA for all 3 primary efficacy measures of hair growth. Microneedling is a safe and a promising tool in hair stimulation and also is useful to treat hair loss refractory to Minoxidil therapy. Keywords: Androgenetic alopecia, dermaroller, hair re-growth, Microneedling, signaling pathways
How to cite this article:
Dhurat R, Sukesh M S, Avhad G, Dandale A, Pal A, Pund P. A randomized evaluator blinded study of effect of microneedling in androgenetic alopecia: A pilot study. Int J Trichol 2013;5:6-11 |
How to cite this URL:
Dhurat R, Sukesh M S, Avhad G, Dandale A, Pal A, Pund P. A randomized evaluator blinded study of effect of microneedling in androgenetic alopecia: A pilot study. Int J Trichol [serial online] 2013 [cited 2023 May 31];5:6-11. Available from: https://www.ijtrichology.com/text.asp?2013/5/1/6/114700 |
| Introduction | |  |
The dermal papilla (DP), a cluster of specialized fibroblasts, regulate the growth and activity of the various cells in the follicle, thereby, playing a key role in the regulation of hair cycling and growth. [1] Hair follicle regeneration begins when signals from the mesenchyme derived DP cells reach multipotent epidermal stem cells in the bulge region.
Large numbers of molecular signals are involved in various phases of the normal hair cycle. The transition of telogen follicles into anagen is associated with activation of Wnt/beta-catenin/Lef1, Sonic Hedgehog (Shh), and STAT3 pathways and down-regulation of bone morphogenetic protein (BMP) signaling. [2],[3],[4] The growth factor BMP-4, also appears to play an important role in suppressing follicular growth and differentiation during telogen.
Androgenetic alopecia (AGA), is the most common type of alopecia in men, which is an androgen mediated event. Circulating androgens, including, dihydrotestosterone (DHT), enter the follicle via the DP's capillaries, bind to the androgen receptor within the DP cells and then activate or repress molecular signaling pathways responsible for premature transition from anagen to catagen and follicular miniaturization. This include suppression of stimulatory pathways of Wnt, Stat 3 and Shh and up-regulation of suppressive pathways (e.g., Dickkopf-related protein 1 and BMP 4). Dkk-1, which is secreted from DP cells in response to DHT pathway, is a potent inhibitor of Wnt pathway. [1] BMP 4 protein also acts through the activation of DKK pathway, thereby inhibiting hair follicular growth. [4]
The only Food and Drug Administration (FDA) approved treatment options for male AGA are Finasteride and Minoxidil, which show cosmetically acceptable new hair growth in modest percentage of patients. Even after more than a decade of their FDA approval, they aren't any new FDA approved treatment modalities.
Recently, Microneedling induced hair growth in mice has been reported. [5],[6] This is the first human study of the use of Microneedling for hair re-growth in men with AGA.
| Materials and Methods | | |
Study population
Men between 20 years and 35 years of age with mild to moderate (III vertex or IV AGA), according to Norwood-Hamilton grading scale were enrolled in the study. Men on Finasteride or other anti-androgenic medications within past 6 months, any known systemic Illness were excluded.
Study design
A 12-week randomized, comparative, evaluator blinded study was conducted at the Department of Dermatology, Lokmanya Tilak Muncipal Medical College and Hospital, Sion, Mumbai from October 2011 to June 2012. A total of 100 men with AGA were enrolled in study after taking an informed consent. They were randomly allocated into Microneedling (N = 50) and Minoxidil group (N = 50) by using the 'tossing coin' method. All patients' scalp was shaved off before treatment to ensure equal length of hair shaft at baseline. In the Microneedling group, patients received a weekly Microneedling procedure on the scalp with 1 ml of 5% Minoxidil lotion applied twice daily. In Minoxidil group, patient applied only 1 ml of 5% Minoxidil lotion twice daily.
Microneedling procedure
The shaven scalp was prepared with betadine and normal saline. A dermaroller of 1.5 mm sized needles was rolled over the affected areas of the scalp in a longitudinal, vertical, and diagonal directions until mild erythema was noted, which was considered as the end point of the procedure. All patients were instructed not to apply Minoxidil on the day of procedure and to resume its application only 24 h after the Microneedling procedure.
Efficacy evaluation
The 3 primary efficacy parameters assessed were: Change from baseline hair count at 12 weeks, patient assessment of hair growth at 12 weeks, and investigator assessment of hair growth at 12 weeks.
Hair counts
The target thinning area of 1 cm diameter, on the vertex was defined by two diagonally placed tattoos to ensure reproducibility. Then, the hair counts were obtained from color Macro-photographs of remnants of the shaven hair in the target area. Macro-photographs were taken at fixed focus, distance, and exposure by use of a specialized adapter attached to the camera [Figure 1]. These images were printed on A4 size Kodak matt-photography paper at baseline and at 12 weeks [Figure 2]. The visible clipped hair was marked with a black dot and these were counted by a blinded evaluator at baseline and at 12 weeks (the target area was once again clipped off at week 12). The resulting hair counts per square centimeter from the fixed area were used to calculate mean change from baseline [Figure 3]. | Figure 1: (a) A specialized adapter attached to the camera; and (b) Photograph of scalp taken at a fixed distance with the help of the adapter
Click here to view |
 | Figure 2: Photographs were printed on Kodak A4 matt‑photography paper and hair were counted by an independent investigator
Click here to view |
 | Figure 3: (a) New hair growth was calculated by subtracting hair count at baseline; and (b) From hair count at week 12
Click here to view |
Investigator assessment
Standardized color global photographs of the affected area were taken with the head in a stereotactic positioning device [Figure 4]. Paired baseline and post-treatment photographs were independently reviewed by a blinded evaluator, with the use of the standardized 7-point rating scale (-3 = greatly decreased, -2 = moderately decreased, -1 = slightly decreased, 0 = no change, +1 = slightly increased, +2 = moderately increased, +3 = greatly increased).
Patient self-assessment
Patients assessed their scalp hair on hair growth assessment scale of 0-4 (0: No improvement; 1: 1-25% improvement; 2: 26-50% improvement; 3: 51-75% improvement; 4: 76-100% improvement).
The results were tabulated on SPSS software using paired t-test and its statistical significance was evaluated.
| Results | | |
Ninety four of the 100 subjects completed the 12 week study period of which 50 were treated with both Microneedling and 5% Minoxidil lotion (Microneedling group) and 44 were treated with only 5% Minoxidil lotion (Minoxidil group) (6 subjects lost to follow-up and they were not considered for efficacy evaluation). Patients demographic and hair loss features at base line were similar among the both groups.
Demographic characteristics
The mean age of the population was 28.6 years. Patients had hair loss for a mean average of 4.5 years (range: 3-10 years).
In Microneedling group, 23 had grade III vertex and 27 had grade IV hair loss. Similarly, in the Minoxidil group, 21 had grade III vertex and 23 had grade IV hair loss.
A total of 94 patients, 20 had been treated with Finasteride and Minoxidil in the past for 6 months to 1 year duration and had reported no improvement, of which twelve were randomized to the Microneedling group and eight to the Minoxidil group.
Efficacy assessment
Hair count
Change from baseline hair count at 12 weeks was a primary efficacy variable. There was steady increase in target area hair count over 12 weeks in subjects of Microneedling group.
The mean change in hair count at week 12 was significantly greater for the Microneedling group compared to the Minoxidil group (91.4 vs. 22.2 respectively, P = 0.039) [Figure 5] and [Table 1]. | Figure 5: Mean hair counts at baseline and at end of 12 weeks in the Microneedling and Minoxidil treated group
Click here to view |
Investigator evaluation
Investigator evaluation of hair growth at week 12 was a primary efficacy variable.
Forty patients in Microneedling group had +2 to +3 response on 7-point visual analogue scale, while none showed the same response in the Minoxidil group [Table 2], [Figure 6] and [Figure 7]. | Figure 6: Grade 3 response on 7‑point evaluation scale in the Microneedling treated group
Click here to view |
 | Figure 7: Grade 0 response on 7‑point evaluation scale in patient no. 1 and grade + 1 response in patient no. 2 in the Minoxidil treated group
Click here to view |
Patient evaluation
Patient subjective evaluation of hair growth at week 12 was a primary efficacy variable. In the Microneedling group, 41 (82%) patients versus only 2 (4.5%) patients in the Minoxidil group reported more than 50% improvement [Table 3].
There was no significant adverse effect in both Microneedling and Minoxidil group.
Other notable findings during the study period were
- Initiation of new hair growth was noticeable by around 6 weeks in Microneedling group and by 10 weeks in Minoxidil group.
- Rapid growth in the existing hair was seen at week 1 in the Microneedling group than Minoxidil group [Figure 8].
 | Figure 8: Earlier and faster hair re‑growth at 1 week noted in Microneedling treated group
Click here to view |
- Twelve men, unsatisfied with Finasteride and Minoxidil in the past, had +1 and +2 responses (4 and 8 men respectively) in Microneedling group on investigator's evaluation. Similar eight unsatisfied men to the previous treatment, showed no change after 12 week study period in the Minoxidil group.
| Discussion | | |
Minoxidil and Finasteride are the only FDA approved treatment modalities for AGA.
Minoxidil is a potassium channel blocker, which leads to new hair growth by causing vasodilatation of scalp blood vessels. In animal studies, topical Minoxidil shortens telogen, causing premature entry of resting hair follicles into anagen, and it probably has a similar action in humans. Minoxidil may also cause prolongation of anagen and increases hair follicle size. [7]
Minoxidil and Finasteride show their greatest efficacy in reducing loss of hair with small percentage of new hair growth seen after at least 4 months of daily usage. [8],[9]
Efficacy of Minoxidil varies from 20% to 40% as per various studies. Patients using monotherapy continue to go bald in spite of therapy. Insignificant cosmetic effect of Minoxidil causes discontinuity of treatment in majority of patients. [10]
DP is the site of expression of various hair growth related genes and a major target for androgen mediated events. Various researches have demonstrated the underlying importance of Wnt proteins and wound growth factors in stimulating DP associated stem cells. [11]
Mechanisms of hair re-growth induced by Microneedling include: [5],[6],[12]
- Release of platelet derived growth factor, epidermal growth factors are increased through platelet activation and skin wound regeneration mechanism
- Activation of stem cells in the hair bulge area under wound healing conditions which is caused by a dermaroller
- Overexpression of hair growth related genes vascular endothelial growth factor, B catenin, Wnt3a, and Wnt10 b.
Studies on repeated Microneedling stimulation by Jeong et al. [5] and Kim et al. [6] showed the enhanced expression of hair related genes and stimulation of hair in mice.
Kim et al. [6] also noted earlier and faster hair re-growth with more shiny texture of the hair in micro needle treated group than the untreated mice group. The authors also suggested that micro needle roller could be useful to treat hair loss refractory to Minoxidil therapy.
The present 12-week study showed that dermaroller along with Minoxidil treated group was statistically superior to Minoxidil treated group in promoting hair growth in men with AGA for all 3 primary efficacy measures of hair count and patient/investigator assessment of hair growth/scalp coverage.
On retrospective questioning of patients after 8 months of completion of the study, at the time of writing the manuscript, all patients in the Microneedling group reported a sustainable response.
The results of this study show that Microneedling is a safe and a promising tool in hair stimulation both for male and female AGA and also is useful to treat hair loss refractory to Minoxidil therapy. We opine that Microneedling procedure should be offered to patients with AGA along with the existing therapeutic modalities for faster hair re-growth and better patient compliance.
However, issues regarding Microneedling viz; different sizes of needles of the dermaroller, frequency, duration and end point of the procedure are yet to be answered.
This is the first study of use of Microneedling in male AGA.
| References | | |
| 1. | Kwack MH, Sung YK, Chung EJ, Im SU, Ahn JS, Kim MK, et al. Dihydrotestosterone-inducible dickkopf 1 from balding dermal papilla cells causes apoptosis in follicular keratinocytes. J Invest Dermatol 2008;128:262-9. 
|
| 2. | Chen D, Jarrell A, Guo C, Lang R, Atit R. Dermal β-catenin activity in response to epidermal Wnt ligands is required for fibroblast proliferation and hair follicle initiation. Development 2012;139:1522-33.
|
| 3. | Reddy S, Andl T, Bagasra A, Lu MM, Epstein DJ, Morrisey EE, et al. Characterization of Wnt gene expression in developing and postnatal hair follicles and identification of Wnt5a as a target of Sonic hedgehog in hair follicle morphogenesis. Mech Dev 2001;107:69-82.
|
| 4. | Plikus MV, Mayer JA, de la Cruz D, Baker RE, Maini PK, Maxson R, et al. Cyclic dermal BMP signalling regulates stem cell activation during hair regeneration. Nature 2008;451:340-4.
|
| 5. | Jeong K, Lee YJ, Kim JE, Park YM, Kim BJ, Kang H. Repeated microneedle stimulation induce the enhanced expression of hair-growth-related genes. Int J Trichology 2012;4:117.
|
| 6. | Kim BJ, Lim YY, Kim HM, Lee YW, Won CH, Huh CH, et al. Hair follicle regeneration in mice after wounding by microneedle roller. Int J Trichology 2012;4:117.
|
| 7. | Messenger AG, Rundegren J. Minoxidil: Mechanisms of action on hair growth. Br J Dermatol 2004;150:186-94.
|
| 8. | Tosti A, Duque-Estrada B. Treatment strategies for alopecia. Expert Opin Pharmacother 2009;10:1017-26.
|
| 9. | Mella JM, Perret MC, Manzotti M, Catalano HN, Guyatt G. Efficacy and safety of finasteride therapy for androgenetic alopecia: A systematic review. Arch Dermatol 2010;146:1141-50.
|
| 10. | Schweiger ES, Boychenko O, Bernstein RM. Update on the pathogenesis, genetics and medical treatment of patterned hair loss. J Drugs Dermatol 2010;9:1412-9.
|
| 11. | Zimber MP, Ziering C, Zeigler F, Hubka M, Mansbridge JN, Baumgartner M, et al. Hair regrowth following a Wnt- and follistatin containing treatment: Safety and efficacy in a first-in-man phase 1 clinical trial. J Drugs Dermatol 2011;10:1308-12.
|
| 12. | O'Toole1 EA, Mellerio JE. Wound healing. In: Burns TB, Cox N, Griffiths C, editors. Rook's Textbook of Dermatology 8 th . Blackwell Publishing. 2010. p14.1-27.
|
[Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5], [Figure 6], [Figure 7], [Figure 8]
[Table 1], [Table 2], [Table 3]
| This article has been cited by | | 1 |
Androgenetic Alopecia: Therapy Update |
|
| Shivali Devjani, Ogechi Ezemma, Kristen J. Kelley, Emma Stratton, Maryanne Senna | | Drugs. 2023; | | [Pubmed] | [DOI] | | | 2 |
Microneedling-Associated Procedures to Enhance Facial Rejuvenation |
|
| Emily A. Spataro, Kennedy Dierks, Paul J. Carniol | | Clinics in Plastic Surgery. 2023; 50(3): 479 | | [Pubmed] | [DOI] | | | 3 |
Noninvasive Hair Rejuvenation |
|
| Jordan Sand, Scott Walen | | Clinics in Plastic Surgery. 2023; 50(3): 509 | | [Pubmed] | [DOI] | | | 4 |
Advances in microneedles research based on promoting hair regrowth |
|
| Yanjun Zhou, Luan Jia, Di Zhou, Gang Chen, Qiang Fu, Ning Li | | Journal of Controlled Release. 2023; 353: 965 | | [Pubmed] | [DOI] | | | 5 |
Possible mechanisms mediating complete regrowth of hair following scalp tattooing in alopecia universalis |
|
| Jan Homolak | | JAAD Case Reports. 2023; | | [Pubmed] | [DOI] | | | 6 |
Recent advances and perspectives of microneedles as transdermal delivery vehicles for analgesic medications |
|
| Jia Liu, Anna Hu, Yuxin Yang, Siqi Huang, Jiangtao Mao, Yuqing Liu, Chuanpin Chen, Zeneng Cheng, Wenjie Liu | | Journal of Drug Delivery Science and Technology. 2023; 84: 104518 | | [Pubmed] | [DOI] | | | 7 |
The efficacy of topical prostaglandin analogs for hair loss: A systematic review and meta-analysis |
|
| Shangxuan Jiang, Zhuolun Hao, Wenli Qi, Zhenxing Wang, Muran Zhou, Nengqiang Guo | | Frontiers in Medicine. 2023; 10 | | [Pubmed] | [DOI] | | | 8 |
Microneedling combined with compound betamethasone in treatment of severe alopecia areata: A case report |
|
| Danning Pei, Lirong Chen, Yue Yao, Linxi Zeng, Guoqiang Zhang | | Frontiers in Immunology. 2022; 13 | | [Pubmed] | [DOI] | | | 9 |
Synergistic effect of microneedle-delivered extracellular matrix compound and radiofrequency on rejuvenation of periorbital wrinkles |
|
| Haiyan Cheng, Ruina Zhang, Fenglin Zhuo | | Frontiers in Medicine. 2022; 9 | | [Pubmed] | [DOI] | | | 10 |
Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial |
|
| Xuelei Liang, Yuan Chang, Haixuan Wu, Yi Liu, Jian Zhao, Leyi Wang, Fenglin Zhuo | | Frontiers in Medicine. 2022; 9 | | [Pubmed] | [DOI] | | | 11 |
Observation on the Efficacy of a Combined Treatment for Moderate and Severe Androgenetic Alopecia Incorporating Electric Microneedles |
|
| Fan Zhang, Yi-Nuo Yang, Jin-Di Feng, Jing-Hui Zhao, Li Wan, Jing Che, Ying Yan, Ning-Ning Guo, Jia-Yu Zhang | | Clinical, Cosmetic and Investigational Dermatology. 2022; Volume 15: 2573 | | [Pubmed] | [DOI] | | | 12 |
Comparison between “5% minoxidil plus 2% flutamide” solution vs. “5% minoxidil” solution in the treatment of androgenetic alopecia |
|
| Gita Faghihi, Fariba Iraji, Amir Hossein Siadat, Mina Saber, Minoo Jelvan, Maedeh Sadat Hoseyni | | Journal of Cosmetic Dermatology. 2022; | | [Pubmed] | [DOI] | | | 13 |
Effects of microneedling with 5% minoxidil topical solution combination therapy in treatment of androgenetic alopecia |
|
| Lingling Jia, Jiachao Xiong, Rong Guo, Yufei Li, Hua Jiang | | Journal of Cosmetic Dermatology. 2022; | | [Pubmed] | [DOI] | | | 14 |
Randomized trial of microneedling combined with 2% minoxidil topical solution for the treatment of female pattern hair loss in a Chinese population |
|
| Yao Zhang, Youyu Sheng, Yibin Zeng, Ruiming Hu, Jun Zhao, Wuqing Wang, Qinping Yang | | Journal of Cosmetic Dermatology. 2022; | | [Pubmed] | [DOI] | | | 15 |
Comparison of Efficacy of Platelet-Rich Plasma (PRP) With PRP Microneedling in Androgenetic Alopecia |
|
| Anjum Muhammad, Nadia Iftikhar, Asher Mashhood, Zulqurnain Saleem, Madhia Sundus, Abrar A Khalid, Shumaila Khan, Safoora Naveed, Waseem Shahid, Umair Ajmal, Afnan Akbar | | Cureus. 2022; | | [Pubmed] | [DOI] | | | 16 |
Microneedle arrays for cutaneous and transcutaneous drug delivery, disease diagnosis, and cosmetic aid |
|
| Vineet Kumar Rai, Ivy Saha, Mahboob Alam, Kumar Nishchaya, Goutam Ghosh, Goutam Rath | | Journal of Drug Delivery Science and Technology. 2022; : 104058 | | [Pubmed] | [DOI] | | | 17 |
Microneedling-Associated Procedures to Enhance Facial Rejuvenation |
|
| Emily A. Spataro, Kennedy Dierks, Paul J. Carniol | | Facial Plastic Surgery Clinics of North America. 2022; 30(3): 389 | | [Pubmed] | [DOI] | | | 18 |
Noninvasive Hair Rejuvenation |
|
| Jordan Sand, Scott Walen | | Facial Plastic Surgery Clinics of North America. 2022; 30(3): 419 | | [Pubmed] | [DOI] | | | 19 |
Minoxidil-loaded hyaluronic acid dissolving microneedles to alleviate hair loss in an alopecia animal model |
|
| Min Jae Kim, Keum-Yong Seong, Da Som Kim, Jea Sic Jeong, So Young Kim, Seungsoo Lee, Seung Yun Yang, Beum-Soo An | | Acta Biomaterialia. 2022; | | [Pubmed] | [DOI] | | | 20 |
A Comprehensive Review of Microneedling as a Potential Treatment Option for Androgenetic Alopecia |
|
| Lingling Jia, Jiachao Xiong, Rong Guo, Yufei Li, Hua Jiang | | Aesthetic Plastic Surgery. 2022; | | [Pubmed] | [DOI] | | | 21 |
The efficacy of LED microneedle patch on hair growth in mice |
|
| Leelawat Kittigul, Jitlada Meephansan, Punyaphat Sirithanabadeekul, Sirashat Hanvivattanakul, Raksawan Deenonpoe, Werayut Yingmema, Kittipong Tantisantisom, Sattra Thongma, Yossawat Rayanasukha, Thitikorn Boonkoom, Punyanuch Adulyaritthikul, Paisan Khanchaitit | | Archives of Dermatological Research. 2022; | | [Pubmed] | [DOI] | | | 22 |
Drug delivery device for the inner ear: ultra-sharp fully metallic microneedles |
|
| Aykut Aksit, Shruti Rastogi, Maria L. Nadal, Amber M. Parker, Anil K. Lalwani, Alan C. West, Jeffrey W. Kysar | | Drug Delivery and Translational Research. 2021; 11(1): 214 | | [Pubmed] | [DOI] | | | 23 |
Non-dermal applications of microneedle drug delivery systems |
|
| Apoorva Panda, V. Anusha Matadh, Sarasija Suresh, H. N. Shivakumar, S. Narasimha Murthy | | Drug Delivery and Translational Research. 2021; | | [Pubmed] | [DOI] | | | 24 |
Microneedling and Its Use in Hair Loss Disorders: A Systematic Review |
|
| Robert S. English, Sophia Ruiz, Pedro DoAmaral | | Dermatology and Therapy. 2021; | | [Pubmed] | [DOI] | | | 25 |
Energy-based Devices for Hair Loss |
|
| James T. Pathoulas, Gretchen Bellefeuille, Ora Raymond, Bisma Khalid, Ronda S. Farah | | Dermatologic Clinics. 2021; 39(3): 447 | | [Pubmed] | [DOI] | | | 26 |
Nonablative radiofrequency for the treatment of androgenetic alopecia: An open-label study |
|
| Rachel K. Lim, Ines Verner, Carlos G. Wambier, Yegor Kolodchenko, Andy Goren | | Dermatological Reviews. 2021; 2(3): 129 | | [Pubmed] | [DOI] | | | 27 |
Response to: “Minimum requirements for reporting clinical trials evaluating the therapeutic potential of platelet-rich plasma” |
|
| Lu Yin, Katerina Svigos, Kumar Sukhdeo, Anthony Ho, Kristen Lo Sicco, Jerry Shapiro | | Journal of the American Academy of Dermatology. 2021; 84(1): e45 | | [Pubmed] | [DOI] | | | 28 |
Comparison of 5% minoxidil lotion monotherapy versus its combination with autologous platelet rich plasma in androgenetic alopecia in hundred males |
|
| Rahul Ray, Aseem Sharma | | Medical Journal Armed Forces India. 2021; 77(3): 355 | | [Pubmed] | [DOI] | | | 29 |
Microneedles in Smart Drug Delivery |
|
| Muhammad Bilal, Shahid Mehmood, Ali Raza, Uzma Hayat, Tahir Rasheed, Hafiz M.N. Iqbal | | Advances in Wound Care. 2021; 10(4): 204 | | [Pubmed] | [DOI] | | | 30 |
A Single-Center Trial to Evaluate the Efficacy and Tolerability of Four Microneedling Treatments on Fine Lines and Wrinkles of Facial and Neck Skin in Subjects With Fitzpatrick Skin Types I-IV: An Objective Assessment Using Noninvasive Devices and 0.33-mm |
|
| Christine E Wamsley, Mikaela Kislevitz, Jennifer Barillas, Deniz Basci, Vishal Kandagatla, Thomas Hitchcock, Yucel Akgul, Jeffrey Kenkel | | Aesthetic Surgery Journal. 2021; 41(11): NP1603 | | [Pubmed] | [DOI] | | | 31 |
Applications of microneedling for various dermatologic indications with a special focus on pigmentary disorders: A comprehensive review study |
|
| Elham Ziaeifar, Fatemeh Ziaeifar, Samaneh Mozafarpoor, Azadeh Goodarzi | | Dermatologic Therapy. 2021; | | [Pubmed] | [DOI] | | | 32 |
Favorable effects of microneedling on long-standing androgenetic alopecia in an elderly man: A case report |
|
| Jun Fujita | | Journal of Cosmetic Dermatology. 2021; 20(2): 588 | | [Pubmed] | [DOI] | | | 33 |
Usefulness of home-use microneedle devices in the treatment of pattern hair loss |
|
| Chihyeon Sohng, Eun Hye Lee, Soo Kyeong Woo, Jun Young Kim, Kyung Duck Park, Seok-Jong Lee, Weon Ju Lee | | Journal of Cosmetic Dermatology. 2021; 20(2): 591 | | [Pubmed] | [DOI] | | | 34 |
Microneedling in androgenetic alopecia; comparing two different depths of microneedles |
|
| Gita Faghihi, Samin Nabavinejad, Fatemeh Mokhtari, Farahnaz Fatemi Naeini, Fariba Iraji | | Journal of Cosmetic Dermatology. 2021; 20(4): 1241 | | [Pubmed] | [DOI] | | | 35 |
Evaluation of adding platelet-rich plasma to combined medical therapy in androgenetic alopecia |
|
| Wafaa Mohammad Ramadan, Arwa Mohammad Hassan, Mayada A. Ismail, Yasmina Ahmed El Attar | | Journal of Cosmetic Dermatology. 2021; 20(5): 1427 | | [Pubmed] | [DOI] | | | 36 |
Evaluation of efficacy of intradermal injection therapy vs derma roller application for administration of QR678 Neo
®
hair regrowth formulation for the treatment of Androgenetic Alopecia—A prospective study
|
|
| Debraj Shome, Rinky Kapoor, Sapna Vadera, Komal Doshi, Ghanshyam Patel, Temoor Mohammad Khan | | Journal of Cosmetic Dermatology. 2021; 20(10): 3299 | | [Pubmed] | [DOI] | | | 37 |
Microneedling for Hair Loss |
|
| Aditya K. Gupta, Emma M. Quinlan, Maanasa Venkataraman, Mary A. Bamimore | | Journal of Cosmetic Dermatology. 2021; | | [Pubmed] | [DOI] | | | 38 |
Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics |
|
| Mark S. Nestor, Glynis Ablon, Anita Gade, Haowei Han, Daniel L. Fischer | | Journal of Cosmetic Dermatology. 2021; | | [Pubmed] | [DOI] | | | 39 |
Comparative clinical assessment of 5% minoxidil topical application with supplemental intradermal meso-solution administration for the management of androgenetic alopecia in men |
|
| Neha Gupta, Sarvraj Kohli | | Indian Journal of Drugs in Dermatology. 2021; 7(2): 67 | | [Pubmed] | [DOI] | | | 40 |
Microneedling: A means of collagen induction therapy |
|
| PragyaA Nair, Jinal Tandel | | Journal of Dermatology and Dermatologic Surgery. 2021; 25(2): 49 | | [Pubmed] | [DOI] | | | 41 |
Microneedling: mechanism of action and indications |
|
| Gemma Fromage | | Journal of Aesthetic Nursing. 2021; 10(4): 144 | | [Pubmed] | [DOI] | | | 42 |
Combination therapy with injectable platelet-rich fibrin and microneedling for male androgenetic alopecia: an evaluation of current practice |
|
| Lucy Millar-Hume | | Journal of Aesthetic Nursing. 2021; 10(9): 408 | | [Pubmed] | [DOI] | | | 43 |
Topical Treatment for Scarring and Non-Scarring Alopecia: An Overview of the Current Evidence |
|
| Camila Oliveira Cardoso, Seila Tolentino, Tais Gratieri, Marcilio Cunha-Filho, Renata Lopez, Guilherme Gelfuso | | Clinical, Cosmetic and Investigational Dermatology. 2021; Volume 14: 485 | | [Pubmed] | [DOI] | | | 44 |
Regenerative Medicine and Hair Loss: Microneedling—Is the Pain Really Worth It? |
|
| Gorana Kuka-Epstein | | International Society of Hair Restoration Surgery. 2021; 31(1): 18 | | [Pubmed] | [DOI] | | | 45 |
A Comprehensive Review of Microneedles: Types, Materials, Processes, Characterizations and Applications |
|
| Faisal Khaled Aldawood, Abhay Andar, Salil Desai | | Polymers. 2021; 13(16): 2815 | | [Pubmed] | [DOI] | | | 46 |
Efficacy of platelet-rich plasma and concentrated growth factor in treating androgenetic alopecia - A retrospective study |
|
| EnoshNirmalkumar Steward, Hiren Patel, Haren Pandya, Hitesh Dewan, Bijal Bhavsar, Urvi Shah, Kartik Dholakia | | Annals of Maxillofacial Surgery. 2020; 10(2): 409 | | [Pubmed] | [DOI] | | | 47 |
Therapeutic efficacy of TriCell CD34+ cell-containing, platelet-rich plasma in alopecia patients |
|
| Kyung Bong Kim, Dae Kwan Kim | | Journal of Cosmetic Medicine. 2020; 4(1): 36 | | [Pubmed] | [DOI] | | | 48 |
A Literature Review of the Microneedle Therapy System for Hair Loss |
|
| Jeong-Hyon Kim, Sung-Eun Shim, Jun-Yeon Kim, Ha-Na Kim, Ji-Min Hwang, Kyeong-Ju Park, Min-Gi Jo, Jun-Yeong Jang, Jung-Hyun Kim, Bonhyuk Goo, Yeon-Cheol Park, Byung-Kwan Seo, Yong-Hyeon Baek, Sang-Soo Nam | | Journal of Acupuncture Research. 2020; 37(4): 203 | | [Pubmed] | [DOI] | | | 49 |
A study on the efficacy of microneedling with minoxidil solution versus microneedling with hair multivitamin solution for the treatment of androgenetic alopecia |
|
| Puri Neerja | | International Journal of Dermatology and Clinical Research. 2020; 6(1): 010 | | [Pubmed] | [DOI] | | | 50 |
Successful Treatment of Alopecia Areata Patches with Triamcinolone Acetonide Using MMP®: Report of 2 Cases |
|
| Marina Barletta, Luciana Gasques | | Skin Appendage Disorders. 2020; 6(4): 229 | | [Pubmed] | [DOI] | | | 51 |
Evaluation of efficacy of QR 678 and QR678 neo hair growth factor formulation for the treatment of female pattern alopecia in patients with PCOS—A prospective study |
|
| Rinky Kapoor, Debraj Shome, Komal Doshi, Ghanshyam Patel, Sapna Vadera | | Journal of Cosmetic Dermatology. 2020; 19(10): 2637 | | [Pubmed] | [DOI] | | | 52 |
Immune cell regulation of the hair cycle |
|
| Etienne C. E. Wang, Claire A. Higgins | | Experimental Dermatology. 2020; 29(3): 322 | | [Pubmed] | [DOI] | | | 53 |
The effectiveness of combination therapies for androgenetic alopecia: A systematic review and meta-analysis |
|
| Yi Zhou, Chenglong Chen, Qian Qu, Chunhua Zhang, Jin Wang, Zhexiang Fan, Yong Miao, Zhiqi Hu | | Dermatologic Therapy. 2020; 33(4) | | [Pubmed] | [DOI] | | | 54 |
Micro needling: A novel therapeutic approach for androgenetic alopecia, A Review of Literature |
|
| Sonia Sofia Ocampo-Garza, Gabriella Fabbrocini, Jorge Ocampo-Candiani, Eleonora Cinelli, Alessia Villani | | Dermatologic Therapy. 2020; 33(6) | | [Pubmed] | [DOI] | | | 55 |
Randomized trial of electrodynamic microneedling combined with 5% minoxidil topical solution for treating androgenetic alopecia in Chinese males and molecular mechanistic study of the involvement of the Wnt/ß-catenin signaling pathway |
|
| Linlin Bao, Haifeng Zong, Sining Fang, Lixiong Zheng, Yuanhong Li | | Journal of Dermatological Treatment. 2020; : 1 | | [Pubmed] | [DOI] | | | 56 |
A review of the treatment of male pattern hair loss |
|
| Katherine York, Nekma Meah, Bevin Bhoyrul, Rodney Sinclair | | Expert Opinion on Pharmacotherapy. 2020; 21(5): 603 | | [Pubmed] | [DOI] | | | 57 |
Evaluation of platelet-rich plasma as a treatment for androgenetic alopecia: A randomized controlled trial |
|
| Jerry Shapiro, Anthony Ho, Kumar Sukhdeo, Lu Yin, Kristen Lo Sicco | | Journal of the American Academy of Dermatology. 2020; 83(5): 1298 | | [Pubmed] | [DOI] | | | 58 |
TOPICAL DELIVERY OF DRUGS USING ETHOSOMES: A REVIEW |
|
| V Sankar, V. Wilson, K. Siram, A. Karuppaiah, S Hariharan, A. Justin | | INDIAN DRUGS. 2019; 56(08): 7 | | [Pubmed] | [DOI] | | | 59 |
Systematic review of the evidence for medical skin needling in aesthetic practice |
|
| Kev Hubbard | | Journal of Aesthetic Nursing. 2017; 6(1): 14 | | [Pubmed] | [DOI] | | | 60 |
Interventions for female pattern hair loss |
|
| Esther J van Zuuren, Zbys Fedorowicz, Jan Schoones | | Cochrane Database of Systematic Reviews. 2016; 2016(10) | | [Pubmed] | [DOI] | | | 61 |
Evaluation of perifollicular inflammation of donor area during hair transplantation in androgenetic alopecia and its comparison with controls |
|
| Nirmal, B., Somiah, S., Sacchidanand, S., Biligi, D., Palo, S. | | International Journal of Trichology. 2013; 5(2): 73-76 | | [Pubmed] | |
|
 |
|
|
|
